PharmaCorp Rx Inc.

TSXV:PCRX Stock Report

Market Cap: CA$61.0m

PharmaCorp Rx Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSXV:PCRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jun 24BuyCA$200,000Dwayne AndersonIndividual500,000CA$0.40
06 Jun 24BuyCA$15,000Terri TatchellIndividual37,500CA$0.40
06 Jun 24BuyCA$125,000Grady BrownIndividual312,500CA$0.40
06 Jun 24BuyCA$125,000Kidd JenileeIndividual312,500CA$0.40
06 Jun 24BuyCA$1,000,001Alan SimpsonIndividual2,500,000CA$0.40
06 Jun 24BuyCA$150,000Glenn FradetteIndividual375,000CA$0.40
06 Jun 24BuyCA$40,000Kimberly CarrollIndividual100,000CA$0.40
06 Jun 24BuyCA$250,000Calvin LeRouxIndividual625,000CA$0.40
06 Jun 24BuyCA$300,000Grant HladunIndividual750,000CA$0.40
06 Jun 24BuyCA$348,760Ken BrownellIndividual871,900CA$0.40
06 Jun 24BuyCA$150,000Paul DaleIndividual375,000CA$0.40

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PCRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders15,653,49213.3%
General Public101,602,38186.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 478.2%.

Top Shareholders

Top 12 shareholders own 13.35% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.31%
Alan Simpson
7,400,000CA$3.8m0%no data
1.79%
Kimberly Carroll
2,100,000CA$1.1m0%no data
1.17%
Glenn Fradette
1,375,000CA$715.0k0%no data
0.83%
Krista Amy
972,525CA$505.7k0%no data
0.74%
Ken Brownell
871,900CA$453.4k0%no data
0.64%
Grant Hladun
750,000CA$390.0k0%no data
0.53%
Calvin LeRoux
625,000CA$325.0k0%no data
0.44%
James Dumont
521,567CA$271.2k4.31%no data
0.32%
Paul Dale
375,000CA$195.0k0%no data
0.27%
Grady Brown
312,500CA$162.5k0%no data
0.27%
Kidd Jenilee
312,500CA$162.5k0%no data
0.032%
Terri Tatchell
37,500CA$19.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 00:49
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaCorp Rx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution